{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:23:00Z","timestamp":1784658180155,"version":"3.55.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compile real-time data on the preferred mydriasis practice patterns for retinopathy of prematurity (ROP) screening in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional online survey was conducted from December 2022 to January 2023, using a self-report online questionnaire which was distributed via email to the members of the European Pediatric Ophthalmological Society and the Greek National ROP Task Force. A six-week period of recruitment was determined, and a reminder email was sent after two weeks. Descriptive statistics were used to explore the data, which was summarized with frequencies and percentages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-six responses were recorded (response rate: 29.5%), representing practices in 55 Neonatal Intensive Care Units from 21 European countries. In 94.5%, the applied mydriatic regimen consists of phenylephrine with at least one muscarinic antagonist, either tropicamide or cyclopentolate. The concentration of phenylephrine ranges from 0.5% to 5%, of tropicamide from 0.25% to 1%, and of cyclopentolate from 0.2% to 1%. The most commonly used regimen (43.6%) contains phenylephrine 2.5% and tropicamide 0.5%, administered either combined or separately. About 54.5% of the reported mydriatic solutions are non-commercial, in-house preparations. Systemic adverse events, including oxygen desaturation, bradycardia and cardiopulmonary arrest were reported in 14.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is considerable heterogeneity in the applied mydriatic regimens for ROP screening in Europe, reflecting the absence of universal guidelines. The wide use of in-house preparations underlines the gap in the pharmaceutical industry. Concern should be raised against the wide use of undiluted commercial drugs, that reach adult dose, in the fragile population of preterm infants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721241234952","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:47:50Z","timestamp":1709696870000},"page":"1803-1809","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Mydriasis for retinopathy of prematurity screening in Europe: A cross-sectional online survey"],"prefix":"10.1177","volume":"34","author":[{"given":"Aikaterini K.","family":"Seliniotaki","sequence":"first","affiliation":[{"name":"2nd Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"},{"name":"Department of Hygiene, Social-Preventive Medicine &amp; Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1391","authenticated-orcid":false,"given":"Konstantinos I.","family":"Bougioukas","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Social-Preventive Medicine &amp; Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lithoxopoulou","sequence":"additional","affiliation":[{"name":"2nd Department of Neonatology &amp; NICU, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Moutzouri","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Diamanti","sequence":"additional","affiliation":[{"name":"2nd Department of Neonatology &amp; NICU, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ziakas","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-022X","authenticated-orcid":false,"given":"Asimina","family":"Mataftsi","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60178-6"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.128"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2996"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.09.032"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01542-x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2019-000448"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00030-9"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06737-1"},{"key":"e_1_3_3_11_2","unstructured":"Phenylephrine Ophthalmic Dosage. Available from: https:\/\/www.drugs.com\/dosage\/phenylephrine-ophthalmic.html. Accessed 20 January 2023."},{"key":"e_1_3_3_12_2","unstructured":"FDA Approved Drug Products: Phenylephrine Ophthalmic Solution. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207926s002lbl.pdf. Accessed 20 January 2023."},{"key":"e_1_3_3_13_2","unstructured":"Tropicamide Ophthalmic Dosage. Available from: https:\/\/www.drugs.com\/dosage\/tropicamide-ophthalmic.html. Accessed 20 January 2023."},{"key":"e_1_3_3_14_2","unstructured":"Cyclopentolate Ophthalmic Dosage. Available from: https:\/\/www.drugs.com\/dosage\/cyclopentolate-ophthalmic.html. Accessed 20 January 2023."},{"key":"e_1_3_3_15_2","article-title":"Stability of extemporaneously prepared ophthalmic solutions for mydriasis","volume":"75","author":"Camp NA","year":"2018","unstructured":"Camp NA, Nadra JT, Hughes SE, et al. Stability of extemporaneously prepared ophthalmic solutions for mydriasis. Am J Heal Pharm 2018; 75: e231\u2013e235.","journal-title":"Am J Heal Pharm"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2004.01.004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726316"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5688\/aj720243"},{"key":"e_1_3_3_19_2","first-page":"1","article-title":"Internet-based surveys: relevance, methodological considerations and troubleshooting strategies","volume":"33","author":"Menon V","year":"2020","unstructured":"Menon V, Muraleedharan A. Internet-based surveys: relevance, methodological considerations and troubleshooting strategies. Gen Psychiatry 2020; 33: 1\u20133.","journal-title":"Gen Psychiatry"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241234952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721241234952","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241234952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:46:05Z","timestamp":1777405565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721241234952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1177\/11206721241234952"],"URL":"https:\/\/doi.org\/10.1177\/11206721241234952","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}